Skip to main content
Future Science OA logoLink to Future Science OA
. 2020 May 29;6(7):FSO587. doi: 10.2144/fsoa-2020-0018

Investigation of Copaifera genus as a new source of antimycobaterial agents

Jéssica Aparecida Alves 1, Fariza Abrão 1, Thaís da Silva Moraes 1, Jaqueline Lopes Damasceno 1, Marcos Fernando dos Santos Moraes 2, Rodrigo Cassio Sola Veneziani 2, Sérgio Ricardo Ambrósio 2, Jairo Kenupp Bastos 3, Mayker Lázaro Dantas Miranda 4, Carlos Henrique Gomes Martins 1,5,*
PMCID: PMC7421775  PMID: 32802394

Abstract

Aim:

This paper reports on the antimycobacterial activity of the oleoresins and extracts obtained from Copaifera spp.

Materials & methods:

The minimum inhibitory concentration (MIC) and fractional inhibitory concentration index techniques helped to evaluate the effect of these oleoresins and extracts against six strains of mycobacteria that cause tuberculosis.

Results & conclusion:

Among the assayed oleoresins and plant extracts, the Copaifera langsdorffii, Copaifera duckei, Copaifera reticulata and Copaifera trapezifolia oleoresins provided the lowest MIC values against some of the tested strains. The combination of Copaifera spp. samples with isoniazid did not evidence any synergistic action. Some Copaifera spp. oleoresins may represent a future source for the discovery of new antimycobacterial drugs due to their low MIC values.

Keywords: : antimicrobial activity, Copaifera spp., crude extracts, Mycobacterium tuberculosis, oleoresins

Lay abstract

The purpose of this paper was to evaluate the antimycobacterial activity of the oleoresins and extracts obtained from Copaifera spp. against a panel of bacteria capable of causing tuberculosis. After completion of the experiments we concluded that oleoresins are better antimicrobial agents than extracts against evaluated bacteria and may represent a future source for the discovery of new antimycobacterial drugs.

Graphical abstract

graphic file with name fsoa-06-587-GA.jpg


Tuberculosis (TB) is one of the oldest diseases known to humankind. It affects and kills thousands of people worldwide. The Mycobacterium genus causes this disease and Mycobacterium tuberculosis is the main species accounting for TB in humans. Pulmonary TB is the most common manifestation of the disease, but it can affect other regions of the body [1,2]. There are several obstacles to the control of TB, including difficulties and delays in diagnosis, drug resistance, lengthy treatment regimens, lack of a highly efficacious vaccine and incomplete understanding of what controls disease transmission, infectivity, reactivation and progression [3,4].

The WHO claims that TB is one of the top ten causes of death in the world. In 2018, an estimated 10 million people developed TB and 1.5 million died from the disease. Approximately 500,000 new cases of multidrug-2 and rifampicin-resistant TB are estimated to emerge annually; only one in three cases were reported to have been treated in 2018 [5]. Multidrug-2 and rifampicin-resistant TB is characterized by resistance to at least rifampicin and isoniazid, the two most powerful drugs against TB, used in standard first-line treatment [6,7]. In addition, adverse reactions, multi-drug resistance and long treatment periods make it difficult for patients to comply with TB therapy. Possible co-infection of patients with HIV/TB reinforces the need to find new therapeutic agents to treat TB [6].

Nontuberculous mycobacteria comprise more than 160 bacterial species, including the Mycobacterium avium complex and Mycobacterium kansasii, some of which may cause disease in humans. Chronic pulmonary infection is the most common clinical manifestation. Although patients suffering from chronic lung diseases are particularly susceptible to nontuberculous mycobacteria pulmonary disease, many affected patients have no apparent risk factors [2].

Indiscriminate use of antimicrobials and potential bacterial recombination have given rise to resistant pathogenic microorganisms, which has made various commercially available drugs ineffective. This scenario has stimulated the search for new therapeutic agents derived from plant species [7–11]. Medicinal plants have long been used to treat several infectious diseases. These plants produce numerous compounds with biological activity, so that they can represent an important source of new antimicrobial agents for drug discovery and development [12–18]. Moreover, higher plant extracts have been considered as promising sources of novel anti-TB leads [19].

The Copaifera genus stands out for its huge variety of secondary metabolites. Copaiba oleoresin is a transparent liquid with variable color and viscosity. Studies on Copaibeiras have revealed that sesquiterpenes and diterpenes are the main compounds in the oleoresin and extracts obtained from these plants [20–22]. The use of Copaifera spp. in folk medicine is diverse, which indicates that these plants display countless pharmacological properties, including significant potential anti-inflammatory, analgesic and antimicrobial action [23]. The antimicrobial activity of the oils obtained from different Copaifera species in Brazil have made them a promising source for the discovery of new and selective agents for the treatment of major infectious diseases [24–33].

Specifically, Copaifera langsdorffii Desf. (Fabacecae-Ceasalpinoidae), popularly known as ‘copaiba’, is a native species of tropical regions of Latin America and is widely distributed in the Brazilian Cerrado and other forests. The oleoresin has a strong antioxidant and anti-inflammatory effects and is composed of several sesquiterpenes and unsaturated diterpene acids [34]. The species Copaifera duckei Dwyer belongs to the family Fabaceae, which produces an oleoresin that comes from the exudation of the trunk of the tree. In folk medicine, traditional communities use this oleoresin through oral or topical administration for various medicinal purposes. Several indications have been described, including wound healing, anti-inflammatory action and antigastric and antiulcer effect, among other digestive diseases [35]. Copaifera reticulata is a medium tree known as ‘copaibeira’ and ‘pau d’óleo’. It is native to tropical regions of south America and grows abundantly in several states of Brazil, like Pará, Amazonas and Ceará. The oleoresin of this plant has been used mainly as healing, anti-inflammatory and antiseptic agent. The main chemical constituents of this oleoresin are mono-, sesqui- and diterpenes; many of its biological activities can be attributed to these compounds [36]. In turn, Copaifera trapezifolia Hayne, a species that is easily found in the Brazilian south-eastern region, is noted for its economic and medicinal importance [37,38]. Leandro et al. [20] investigated the antibacterial activity of the hydroalcoholic extract obtained from C. trapezifolia leaves (CTE) against microorganisms that cause dental caries and apical periodontitis, to find that C. trapezifolia leaves exhibits antibacterial activity against some of the tested microorganisms under the employed experimental conditions. The authors emphasized that this plant species can be an important source of biologically active compounds and aid in the search for new effective and safe agents that can act against oral pathogens.

Considering the pharmacological potentials of Brazilian Copaifera species [39], this study aimed to evaluate the antimycobacterial activity of the oleoresins and hydroalcoholic crude extracts obtained from Copaifera spp. leaves against some mycobacterial species and the interaction between compounds from this plant species and the antibiotic isoniazid.

Materials & methods

Plant material & chemical characterization

Copaifera leaves and oleoresins (when available) were collected in different states, between August 2012 and May 2014, which was authorized by the Brazilian government through SISBIO (35143-1) and CGEN (010225/2014-5). Table 1 contains information about voucher specimens. To extract the oleoresins, a hole of approximately 1 inch wide and 3 feet above the ground was made into the center of the trunk of the tree with an auger. The oleoresin was drained into an amber bottle by using a pipe connected to a filter and the hole was then properly sealed [40]. The leaf extracts were prepared as described in Furtado et al. [41].

Table 1. . Collection information concerning the Copaifera species.

Copaifera species Location (city/state) Herbarium Identification number
Copaifera langsdorffii Cajuru/SP SPFR 14438
Copaifera duckei Belém/PA EMBRAPA 175206
Copaifera reticulata Brasil Novo/PA EMBRAPA 175266
Copaifera multijuga Manacapuru/AM EMBRAPA 180069
Copaifera lucens Rio de Janeiro/RJ JBRJ§ 474303
Copaifera oblongifolia Pirajuba/MG SPFR 14437
Copaifera trapezifolia Rio de Janeiro/RJ EMBRAPA 178494

SPFR: Herbarium of the Department of Biology, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo (SPFR), Brazil.

EMBRAPA: Brazilian Agricultural Research Corporation (Embrapa Eastern Amazon), Brazil.

§

JBRJ: Rio de Janeiro Botanical Garden, Brazil.

Microorganisms

To evaluate the antimycobacterial activity of the oleoresins and the hydroalcoholic crude extracts from Copaifera spp., the following American Type Culture Collection (ATCC) mycobacteria and clinical isolates (were kindly supplied by Adolfo Lutz Institute) were used: M. tuberculosis H37Rv (ATCC 27294), M. tuberculosis (clinical isolate CF 16), M. kansasii (ATCC 12478), M. kansasii (clinical isolate 2776), M. avium (ATCC 25291) and M. avium complex (clinical isolate 2781).

Determination of MIC

To evaluate the antimycobacterial activity of the samples, the MIC was determined by microdilution in a microplate. Resazurin was used to reveal bacterial growth by the resazurin microtiter assay (REMA) method procedure adapted from Palomino et al. [42]. The experiment was conducted in triplicate.

The oleoresins and the hydroalcoholic crude extracts were dissolved in DMSO and serially diluted in Middlebrook 7H9 broth before inoculation. The concentrations of the tested compounds ranged from 31.25 to 2000 μg ml-1. Isoniazid, dissolved in DMSO, was used as standard drug at concentrations ranging from 0.015 to 1.0 μg ml-1. The inoculum was prepared by introducing a range of colonies grown in Ogawa–Kudoh (LaborClin) in a tube containing glass beads with 500 μl of sterile water. A 200-μl aliquot was transferred to a tube containing 2 ml of 7H9 broth, incubated at 37°C for 7 days and compared with McFarland scale 1. After the inoculum was standardized, it was diluted with 7H9 broth at a 1:25 ratio. Growth controls containing no antibiotic and sterility controls without inoculation were also included. The plates were incubated at 37°C for 7 days. Subsequently, 30 μl of 0.02% resazurin aqueous solution was added to each well. After standing for 18 h, a blue color (coloring resazurin solution) was interpreted as lack of bacterial growth, whereas a pink color indicated the presence of viable micro-organisms. MIC was defined as the lowest drug concentration that was able to inhibit 90% growth of the mycobacterium strain. The assay was conducted in triplicate.

Determination of the fractional inhibitory concentration index

The activities of combinations of the oleoresins and hydroalcoholic crude extracts with isoniazid were evaluated by fractional inhibitory concentration index (FICI) for each of the tested mycobacteria. Checkerboard assays were performed according to the protocol previously described by Bhusal et al. [43] with modifications to investigate the in vitro antimicrobial efficacy of the combination of the compounds with the positive control (isoniazid). The whole experiment was repeated three-times. To determine FICI, the concentrations of oleoresins, hydroalcoholic crude extracts and isoniazid were the same as the concentrations used in the MIC assay. The bacterial inoculum was also employed at the same concentration and the inoculum was prepared in the same way described in the section about the MIC assay.

Serial twofold dilutions of compounds and isoniazid were mixed in each well of a 96-well microtiter plate. Fifty-microliter aliquots of the antimicrobial agent (oleoresins or extracts) at an initial concentration of 8000 μg ml-1 were added in vertical and horizontal orientation, respectively. Next, 100 ml of 1 × 108 CFU/ml fresh bacterial suspension was added to each well and incubated as mentioned previously. After 7 days of incubation at 37°C, resazurin was added to each well to reveal bacterial growth.

FICIs were calculated according to the following formula: FICI = (MIC of antimicrobial agent in combination with isoniazid/MIC of antimicrobial agent alone) + (MIC of isoniazid in combination with antimicrobial agent/MIC of isoniazid alone). Synergism was defined as FICI ≤0.5; additive effect was defined as 0.5 < FICI <1; indifference was defined as 1 ≤ FICI <4 and antagonism was defined as FICI ≥ 4 [44].

Results & discussion

Silva et al. [40] and in Furtado et al. [41] described the chemical characterization of all the oleoresins and leaf extracts. Here, we have investigated the antimycobacterial activity of the oleoresins and hydroalcoholic crude extracts obtained from the leaves of Copaifera spp. by determining the MIC and the FICI. Table 2 summarizes the MIC values determined for the oleoresins and the hydroalcoholic extracts obtained from the leaves of Copaifera spp. against the tested mycobacteria.

Table 2. . MIC - μg ml-1 results obtained for the oleoresins and hydroalcoholic crude extracts obtained from Copaifera spp. against mycobacteria.

Extract/oleoresin/PC Mycobacterium avium - I.C 2781 Mycobacterium avium - ATCC 25291 Mycobacterium kansasii - I.C 2776 Mycobacterium kansasii - ATCC 12478 Mycobacterium tuberculosis – H37Rv ATCC 27294 Mycobacterium tuberculosis I.C CF 16
Copaifera trapezifolia – extract 1000 1000 >2000 1000 1000 500
Copaifera oblongifolia – extract 1000 500 >2000 500 250 500
Copaiferaduckei – extract 1000 500 >2000 1000 125 500
Copaifera lucens – extract 1000 500 1000 250 125 500
Copaifera langsdorffii – oleoresin 500 125 125 62.5 250 125
Copaifera duckei – oleoresin 500 62.5 125 62.5 62.5 125
Copaifera reticulata – oleoresin 125 125 125 250 500 62.5
Copaifera oblongifolia – oleoresin 125 125 500 500 250 125
Copaifera multijuga – oleoresin >2000 2000 1000 1000 250 125
C. trapezifolia – oleoresin 1000 500 125 500 125 62.5
Isoniazid (PC) 1.0 >1.0 1.0 1.0 0.6 1.0

ATCC: American Type Culture Collection; PC: Positive control.

MIC ranged from 62.5 μg ml-1 to values above 2000 μg ml-1. According to Holetz et al. [45], crude extracts with MIC values lower than 100 μg ml-1, between 100 and 500 μg ml-1, from above 500 to 1000 μg ml-1 and greater than 1000 μg ml-1 display good antimicrobial activity, moderate antibacterial activity, weak antibacterial activity and absence of antibacterial activity, respectively. Other authors have considered that MICs ≤200 μg ml-1 for extracts indicate good activity against M. tuberculosis [46].

The C. duckei oleoresin displayed MIC of 62.5 μg ml-1 against M. avium (ATCC 25291), M. kansasii (ATCC 12478) and M. tuberculosis (ATCC 27294). The same results were found for the C. langsdorffii oleoresin against M. kansasii (ATCC 12478) and the C. reticulata oleoresin against M. tuberculosis (clinical isolate CF16). These results demonstrated the great potential of these oleoresins against some mycobacterial species.

Based on the criteria of Holetz et al. [45], these results corresponded to good antimycobacterial activity and demonstrated that compounds from natural products are an important source of lead drugs for the research and development of new antimycobacterial agents.

The hydroalcoholic extracts obtained from C. duckei, Chionanthus lucens, C. langsdorffii, C. duckei, C. reticulata, Copaifera oblongifolia, C. trapezifolia and Copaifera multijuga leaves displayed MIC of 125 μg ml-1 against the mycobacteria M. kansasii (clinical isolate), M. tuberculosis (ATCC and clinical isolate) and M. avium (ATCC and clinical isolate). The hydroalcoholic extracts obtained from C. lucens and C. oblongifolia leaves and the oleoresins obtained from C. langsdorffii, C. reticulata, C. oblongifolia and C. multijuga leaves presented MIC of 250 μg ml-1 against M. tuberculosis (ATCC) and M. kansasii (ATCC). The hydroalcoholic extracts obtained from C. trapezifolia, C. oblongifolia, C. duckei and C. lucens leaves and the oleoresins obtained from C. langsdorffii, C. duckei, C. reticulata, C. oblongifolia and C. trapezifolia leaves exhibited MIC of 500 μg ml-1 against M. kansasii (ATCC and clinical isolate), M. tuberculosis (ATCC and clinical isolate) and M. avium (ATCC and clinical isolate). These results were considered moderate for antimycobacterial activity.

Natural antimicrobial products may lead to different results. The differences observed between the oleoresins and the hydroalcoholic extracts obtained from leaves herein might stem from the distinct composition of the oleoresins and the extracts. From a chemical viewpoint, Copaifera oleoresins comprise a diterpene acid solution in an essential oil consisting mainly of sesquiterpenes [40,41,47]. Currently, over 70 sequiterpenes have been identified in different Copaifera species. From a biological standpoint, the oleoresin consists of a waste product or detoxification plant organism and acts to protect the plant against animals, fungi and bacteria [48]. Additionally, phytochemical studies on these plants have concluded that the hydroalcoholic crude extracts obtained from ‘copaiba’ leaves are rich in polar compounds, which can be extracted by aqueous alcohol extraction. Thus, Furtado et al. [41] have recently described the presence of phenolic compounds like flavonoid heterosides and galloylquinic acid derivatives in such extracts. The quercetin flavonoids and kaempferol-3-O-α-L-rhamnopyranoside substances were first described in the hydroalcoholic extract of the aerial parts of C. landsgorffii. This class of substances is well known for their different biological activities, especially their anticancer and antioxidant actions [49]. According to Sikkema et al. [50], an important feature accounting for the antimicrobial activity of oils is the presence of hydrophobic lipid components that can partition the bacterial cell membrane, thereby disintegrating structures and making them more permeable.

In most cases herein, the crude hydroalcoholic extracts obtained from the leaves proved to be less effective in fighting bacteria as seen in the MIC results. This is because the oleoresins contain higher concentration of active molecules than the crude hydroalcoholic extracts obtained from the leaves [23].

In this study, the MIC results that were chosen to determine the FICI values were less than or equal to 125 μg ml-1, these MIC values gave the best results and inhibited mycobacterial growth the most during the tests. The oleoresins and the hydroalcoholic crude extracts that provided MIC values in this range were the C. trapezifolia, C. duckei, C. langsdorffii, C. reticulata, C. oblongifolia and C. multijuga oleoresins and the extracts obtained from C. duckei and C. lucens.

The FICI results obtained after evaluation of the synergistic action between the oleoresins or the hydroalcoholic crude extracts and isoniazid against each of the tested mycobacteria did not evidence any synergism. Indeed, the results were antagonistic or indifferent (data not shown). Even though our data did not support any synergy between the oleoresins or extracts and isoniazid, we investigated the combination of these compounds in an attempt to improve the antimycobacterial activity. Hochfellner et al. [51] evaluated the interaction between quinolone and indoloquinazoline alkaloids with rifampicin or isoniazid against Mycobacterium smegmatis (ATCC 14468). The authors did not find satisfactory interaction between the evaluated molecules and rifampicin or isoniazid.

According to Van et al. [52], antagonistic interactions should not be ignored when investigating interactions in plant-based studies. These authors reported that the increasing number of scientific works exploring interactions among herbal substances is encouraging and relevant in our ongoing quest to understand the mechanisms of action of herbal medicine.

It is worth mentioning that the oils and extracts used in the MIC tests and in combination with isoniazid herein were weighed against a group of bacteria that are difficult to treat because they have cell wall and different proteins. Bearing this in mind, we can consider that the MIC values obtained herein are promising. Not to overlook possible associations of the substances tested herein with different drugs, we shall conduct future studies using a greater variety of drug combinations, which will hopefully result in new treatment alternatives.

Moreover, the literature contains few studies on the use of Copaifera against mycobacteria, another reason this study is important to guide future research in this field.

Conclusion

The oleoresins obtained from C. langsdorffii, C. duckei, C. reticulata and C. trapezifolia inhibited the growth of the mycobacteria M. kansasii (ATCC), M. tuberculosis (ATCC and clinical isolate) and M. avium (ATCC) satisfactorily. The FICI showed that the combination of one of the extracts or oleoresins tested herein with isoniazid exerted antagonistic or indifferent effects on the tested mycobacteria.

In conclusion, the results of this study, especially the MIC values lower than 100 μg ml-1, suggested that investigation into the properties of the oleoresins and extracts obtained from some Copaifera species could contribute to expanding scientific knowledge about the antimycobacterial activity of this plant genus and aid the discovery of new antimycobacterial drugs.

Future perspective

Although TB has become a treatable disease thanks to the emergence of antibiotics, it is still a difficult disease to treat – treatment lasts long and a large amount of antibiotics is used by the patient. Increased bacterial resistance is a reality in which scientists seek to discover new drugs that can fight infection with minimal damage to the patient. Existing drugs have a large number of side effects and should be replaced with safe molecules. In this context, medicinal plants have been explored as sources of molecules with promising antibacterial activity. Few studies involving antimycobacterial activity and Brazilian medicinal plants have resulted in satisfactory effects. The oleoresins used in this study proved to be safe in the toxicity tests conducted by our research group. The oleoresins evaluated here are promising in the search for new antimycobacterial compounds. It is necessary to understand their mechanism of action and to undertake further studies on molecules obtained from Copaifera spp. oleoresins.

The results suggest that the oleoresins obtained from some Copaifera species can contribute to the discovery of new antimycobacterial drugs, but studies involving its mechanism of action should be undertaken.

Executive summary.

  • The Copaifera langsdorffii, Copaifera duckei, Citrus reticulata, Copaifera multijuga and Copaifera trapezifolia oleoresins were effective against the Mycobacterium spp evaluated in this study.

  • Among the investigated Copaifera species, C. duckei displayed the best antimycobacterial results.

  • Oleoresins in the absence of isoniazid were more effective.

Footnotes

Author contributions

JK Bastos, CHG Martins, SR Ambrósio and RCS Veneziani conceived and designed the experiments. SR Ambrósio, MLD Miranda, MF dos S Moraes and RCS Veneziani provided Copaifera spp. leaves hydroalcoholic extract and oleoresin. JA Alves, F Abrão, T da S Moraes, JL Damasceno conceived and designed the experiments. JA Alves, JK Bastos, CH Martins wrote the manuscript. All authors contributed to the manuscript preparations and also approved it for submission.

Financial & competing interests disclosure

This work was kindly supported by the São Paulo Research Foundation – FAPESP, Processes number # 2011/13630-7 and # 2012/25237-0 and Coordination for the Improvement of Higher Level Personnel (CAPES) and National Council for Scientific and Technological Development (CNPq). The authors have no affiliations or financial involvement with any organization or entity with a financial interest in this work or financial conflict.

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

  • 1.Lin HC, Perng CL, Lai YW. et al. Molecular screening of multidrug-resistance tuberculosis by a designated public health laboratory in Taiwan. Eur. J. Clin. Microbiol. Infect. Dis. 36(12), 2431–2439 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Wassilew N, Hoffmann H, Andrejak C, Lange C. Pulmonary disease caused by non-tuberculous mycobacteria. Respiration 91(5), 386–402 (2016). [DOI] [PubMed] [Google Scholar]
  • 3.Zumla A, Raviglione M, Hafner R. et al. Tuberculosis. N. Engl. J. Med. 368(8), 745–755 (2013). [DOI] [PubMed] [Google Scholar]
  • 4.Hawn TR, Day TA, Scriba TJ. et al. Tuberculosis vaccines and prevention of infection. Microbiol. Mol. Biol. Rev. 78, 650–671 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.WHO. Rapid Communication: Key Changes to the Treatment of Drug-Resistant Tuberculosis. WHO, Geneva, Switzerland: (2019). [Google Scholar]
  • 6.WHO. Policy Statement: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. WHO, Geneva,Switzerland: (2011). [PubMed] [Google Scholar]
  • 7.Lempens P, Meehan CJ, Vandelannoote K. et al. Isoniazid resistance levels of mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci. Rep. 8(1), 3246 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Trias J, Gordon MS. Innovative approaches to novel antibacterial drug discovery. Curr. Opin. Biotechnol. 8, 757–762 (1997). [DOI] [PubMed] [Google Scholar]
  • 9.Achar J, Hewison C, Cavalheiro AP. et al. Off-label use of bedaquiline in children and adolescents with multidrug-resistant tuberculosis. Emerg. Infect. Dis. 15, 23 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Alvarez C, Labarca J, Hall M. Staphylococcus prevention strategies aureus resistant to methicillin (MRSA) in Latin America. Braz. J. Infect. Dis. 14, 108–120 (2010). [DOI] [PubMed] [Google Scholar]
  • 11.Aguiar JS, Araujo RO, Rodrigues MDO. et al. Antimicrobial, antiproliferative and proapoptotic activities of extract, fractions and isolated compounds from the stem of Erythroxylum caatingae Plowman. Int. J. Mol. Sci. 13, 4124–4140 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Gomes NGM, Pereira DM, Valentão P. et al. Hybrid MS/NMR methods on the prioritization of natural products: applications in drug discovery. J. Pharm. Biomed. Anal. 17, 31401–31402 (2017). [DOI] [PubMed] [Google Scholar]
  • 13.Saleem M, Nazir M, Ali MS. et al. Antimicrobial natural products: an update on future antibiotic drug candidates. Nat. Prod. Rep. 27, 238–254 (2009). [DOI] [PubMed] [Google Scholar]
  • 14.Sharifi-Rad J, Salehi B, Stojanović-Radić ZZ. et al. Medicinal plants used in the treatment of tuberculosis - ethnobotanical and ethnopharmacological approaches. Eclectic Chem. 34, 7–13 (2009). [Google Scholar]
  • 15.Tiwari BK, Valdramidis VP, Donnell CPO. et al. Application of natural antimicrobials for food preservation. Biotechnol. Adv. 57(14), 5987–6000 (2009). [DOI] [PubMed] [Google Scholar]
  • 16.Mishra SK, Tripathi G, Kishore N. et al. Drug development against tuberculosis: impact of alkaloids. Eur. J. Med. Chem. 137, 504–544 (2017). [DOI] [PubMed] [Google Scholar]
  • 17.Rodrigues Felix C, Gupta R, Geden S. et al. Selective killing of dormant Mycobacterium tuberculosis by marine natural products. Antimicrob. Agents Chemother. 25, 61 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim. Biophys. Acta 1830, 3670–3695 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]; •• Discovers novel sources of antibacterial products.
  • 19.Farah SI, Abdelrahman AA, North EJ, Chauhan H. Opportunities and challenges for natural products as novel antituberculosis agents. Assay Drug Dev. Technol. 14, 29–38 (2016). [DOI] [PubMed] [Google Scholar]
  • 20.Leandro LF, Moraes TS, Oliveira PF. et al. Assessment of the antibacterial, cytotoxic and mutagenic potential of the phenolic-rich hydroalcoholic extract from Copaifera trapezifolia Hayne leaves. J. Med. Microbiol. 65, 937–950 (2016). [DOI] [PubMed] [Google Scholar]; • Highlights the importance of Copaifera genus.
  • 21.Moraes T da S, Leandro LF, de Silva LO. et al. In vitro evaluation of Copaifera oblongifolia oleoresin against bacteria causing oral infections and assessment of its cytotoxic potential. Curr. Pharm. Biotechnol. 17, 894–904 (2016). [DOI] [PubMed] [Google Scholar]; • Highlights the importance of Copaifera genus.
  • 22.Borges CHG, Cruz MG, Carneiro LJ. et al. Copaifera duckei oleoresin and its main non volatile terpenes: in vitro schistosomicidal properties. Chem. Biodivers. 13, 1348–1356 (2016). [DOI] [PubMed] [Google Scholar]; • Highlights the importance of Copaifera genus.
  • 23.Leandro LM, Vargas FS, Barbosa PCS. et al. Chemistry and biological activities of terpenoids from Copaiba (Copaifera spp.) oleoresins. Molecules 17, 3866–3889 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Santos AO, Ueda-Nakamura T, Day Son BP. et al. Antimicrobial activity of brazilian copaiba oils obtained from different species of the genus Copaifera. Mem. Inst. Oswaldo Cruz 103, 277–281 (2008). [DOI] [PubMed] [Google Scholar]
  • 25.Tobouti PL, de Andrade Martins TC, Pereira TJ. et al. Antimicrobial activity of copaiba oil: a review and a call for further research. Biomed. Pharmacother. 27, 93–99 (2017). [DOI] [PubMed] [Google Scholar]
  • 26.Veiga Junior VF, Pinto AC, Calixto JB. et al. Phytochemical and anti-oedematogenic studies of commercial copaíba oils available in Brazil. Phytother. Res. 15, 476–480 (2001). [DOI] [PubMed] [Google Scholar]
  • 27.Heck MC, Viana LA, Vicentini VEP. Importance of Copaifera sp. (Copaiba) oil. Ver. Saúde e Biol. 7(1), 82–90 (2017). [Google Scholar]
  • 28.Souza AB, Martins CHG, Souza MGM. et al. Antimicrobial activity of terpenoids from Copaifera langsdorffii Desf. against cariogenic bacteria. Phytother. Res. 25, 215–220 (2011). [DOI] [PubMed] [Google Scholar]
  • 29.Souza AB, Souza MGM, Moreira MA. et al. Antimicrobial evaluation of diterpenes from Copaifera langsdorffii oleoresins periodontal against anaerobic bacteria. Molecules 16, 9611–9619 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Abrão F, Costa LDA, Alves JM. et al. Copaifera langsdorffii oleoresins and its isolated compounds: antibacterial effect and antiproliferative activity in cance cell lines. BMC Complement. Altern. Med. 15, 443 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]; • Highlights the importance of Copaifera genus.
  • 31.Santiago KB, Conti BJ, Murbach RT. et al. Immunomodulatory action of Copaifera spp. oleoresins on cytokine production by human monocytes. Biomed. & Pharmacother. 70, 12–18 (2015). [DOI] [PubMed] [Google Scholar]
  • 32.Bardají DKR, da Silva JJM, Bianchi TC. et al. Copaifera reticulata oleoresin: chemical characterization and antibacterial properties against oral pathogens. Anaerobe 40, 18–27 (2016). [DOI] [PubMed] [Google Scholar]
  • 33.Abrão F, Alves JA, Andrade G. et al. Antibacterial effect of Copaifera duckei Dwyer oleoresin and its main diterpenes against oral pathogens and their cytotoxic effect. Front. Microbiol. 9, 201 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]; • Highlights the importance of Copaifera genus.
  • 34.Almeida LFR, Portella RO, Bufalo J. et al. Non-oxygenated sesquiterpenes in the essential oil of Copaifera langsdorffii Desf. increase during the day in the dry season. PLoS ONE 11, e0149332 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Carvalho HO, Santos IVF, Rocha CF. et al. Effect of the treatment of Copaifera duckei oleoresin (copaiba) in streptozotocin-induced diabetic rats. Braz. J. Pharmacogn. 28, 724–731 (2018). [Google Scholar]
  • 36.Geris R, Silva IG, Silva HHG. et al. Diterpenoids from Copaifera reticulata Ducke with larvicidal activity against Aedes aegypti (L.) (Diptera, Culicidae). Rev. Inst. Med. Trop. S. Paulo 50, 25–28 (2008). [DOI] [PubMed] [Google Scholar]
  • 37.Veiga VF, Pinto AC, Lima HC. The essential oil composition of Copaifera trapezifolia Hayne leaves. J. Essent. Oil Res. 18, 430–431 (2006). [Google Scholar]
  • 38.Milani JF, Rocha JF, Teixeira SP. Oleoresin glands in copaiba (Copaifera trapezifolia Hayne: leguminosae), a Brazilian rainforest tree. Trees 26, 769–775 (2012). [Google Scholar]
  • 39.Trindade R, Silva JK, Setzer WN. Copaifera of the Neotropics: a review of the phytochemistry and pharmacology. Int. J. Mol. Sci. 19, 1511 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Silva JJM, Crevelin EJ, Carneiro LJ. et al. Development of a validated ultra-high-performance liquid chromatography tandem mass spectrometry method for determination of acid diterpenes in Copaifera oleoresins. J. Chromat. A. 1515, 81–90 (2017). [DOI] [PubMed] [Google Scholar]
  • 41.Furtado RA, de Oliveira PF, Senedese JM. et al. Assessment of genotoxic activity of oleoresins and leaves extracts of six Copaifera species for prediction of potential human risks. J. Ethnopharmacol. 221, 119–125 (2018). [DOI] [PubMed] [Google Scholar]
  • 42.Palomino CJ, Martin M, Camacho H. et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrobial. Agents Chemother. 46, 2720–2722 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Bhusal Y, Shiohira CM, Yamane N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 26(4), 292–297 (2005). [DOI] [PubMed] [Google Scholar]
  • 44.Lewis RE, Diekema DJ, Messer SA. et al. Comparison of test, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemother. 49, 345–351 (2002). [DOI] [PubMed] [Google Scholar]
  • 45.Holetz FB, Pessini LG, Sanches RN. et al. Screening of some plants used in the Brazilian folk medicine for the treatment of infectious diseases. Mem. Inst. Oswaldo Cruz 97, 1027–1031 (2002). [DOI] [PubMed] [Google Scholar]; •• Highlights the importance of initial screening of medicinal plants.
  • 46.Mota APP, Dantas JCP, Frota CC. Antimicrobial activity of essential oils from Lippia alba, Lippia sidoides, Cymbopogon citrates, Plectranthus amboinicus, and Cinnamomum zeylanicum against Mycobacterium tuberculosis. Cienc. Rural 48, e20170697 (2018). [Google Scholar]
  • 47.Cascon V, Gilbert B. Characterization of the chemical composition of oleoresins of Copaifera guianensis Desf., Copaifera duckei Dwyer and Copaifera multijuga Hayne. Phytochemistry 5, 773–778 (2000). [DOI] [PubMed] [Google Scholar]
  • 48.Veiga Junior VF, Pinto AC. The Copaifera L. genus. Quim. Nova 25, 273–289 (2002). [Google Scholar]
  • 49.Sousa JPB, Brancalion APS, Junior Milton G. et al. A validated chromatographic method for the determination of flavonoids in Copaifera langsdorffii by HPLC. Nat. Prod. Commun. 7, 25–28 (2012). [PubMed] [Google Scholar]
  • 50.Sikkema J, De Bont JAM, Poolman B. Interactions of cyclic hydrocarbons with biological membranes. J. Biol. Biochem. 269, 8022–8028 (1994). [PubMed] [Google Scholar]
  • 51.Hochfellner C, Evangelopoulos D, Zloh M. et al. Antagonistic effects of indoloquinazoline alkaloids onantimycobacterial activity of evocarpine C. J. App. Microbiol. 118, 864–872 (2015). [DOI] [PubMed] [Google Scholar]
  • 52.Van Vuuren S, Viljoen A. Plant-based antimicrobial studies – methods and approaches to study the interaction between natural products. Planta Med. 77, 1168–1182 (2011). [DOI] [PubMed] [Google Scholar]

Articles from Future Science OA are provided here courtesy of Taylor & Francis

RESOURCES